News brief­ing: Roche shows off more MS, NMOSD da­ta; Gala­pa­gos and Gilead clear PhI­Ia pri­ma­ry end­points but re­port SAEs

Roche’s Genen­tech an­nounced on Fri­day that it has even more da­ta to back Ocre­vus as a mul­ti­ple scle­ro­sis treat­ment.

The drug hit the mar­ket three years ago, in what CEO Sev­erin Schwan has called the most suc­cess­ful launch in the com­pa­ny’s 124-year his­to­ry.

This week­end, the biotech says it will bring new da­ta to MSVir­tu­al2020 that show Ocre­vus’ ben­e­fit in pa­tients who have re­laps­ing-re­mit­ting mul­ti­ple scle­ro­sis (RRMS), and have ex­pe­ri­enced a sub­op­ti­mal re­sponse to a pri­or dis­ease-mod­i­fy­ing ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.